PRESS RELEASES

HAS Healthcare Advanced Synthesis launches as an independent business

HAS Healthcare Advanced Synthesis launches as an independent business

Biasca, SwitzerlandJanuary 13, 2022 – HAS Healthcare Advanced Synthesis SA (the “Company”), a full-service contract development and manufacturing organization (CDMO) delivering high-quality, exclusive, personalized solutions to its healthcare clients, today announces its launch as an independent business. Originally established as part of the Helsinn Group by the Braglia family, under the name Helsinn Advanced Synthesis SA, the Company has been a CDMO since 1984.

The transition into a privately owned, independent company reflects the growth of the Company over the past years and a desire to fully focus the Company on delivering the best CDMO standards to its healthcare clients. As a subsidiary of the newly formed 3B Future Holding SA (also wholly owned by the Braglia Family) and supported by a team of passionate senior executives with extensive experience and skills in contract manufacturing for the pharmaceutical industry, HAS Healthcare Advanced Synthesis believes it is well placed to serve its clients as an innovative and technology-advanced manufacturing plant. The Company’s executive team will remain in place and Waldo Mossi, previously General Manager, has been appointed as Chief Executive Officer. Mossi, who has been with the Company for 27 years, has led the Company as General Manager for the past 8 years.

HAS Healthcare Advanced Synthesis’ dedicated team will continue to offer exclusive, personalized services to its clients, including the development and manufacturing of Active Pharmaceutical Ingredients (APIs), cGMP Advanced Intermediates, High Potency APIs (HPAPIs) and anticancer compounds, and to support its clients with their analytical and regulatory requirements. Over the years, the Company has always strived to deliver a cutting-edge service to its clients on their major projects and has done so by investing in innovative technology within its plants while striving to reduce the impact of its activities on the environment. Going forward,

HAS Healthcare Advanced Synthesis intends to build new laboratories to further strengthen its pharmaceutical offering and to anticipate future regulatory requests.

To view the new HAS Healthcare Advanced Synthesis website, please follow this link.

Waldo Mossi, CEO of HAS Healthcare Advanced Synthesis, commented: “We are thrilled to announce this exciting next step for HAS Healthcare Advanced Synthesis. Having spent the last decade developing our facilities, with investment totalling over CHF 100 million, we are excited by the prospect of supporting our clients and all of their manufacturing needs as an independent business. Our passion to deliver the best outcomes will remain unchanged, underpinned by the experience and know-how synonymous with our team. I feel honored to serve as CEO and to have been given this golden opportunity to lead HAS Healthcare Advanced Synthesis through this important milestone for the Company.

Riccardo BragliaChairman of the HAS Healthcare Advanced

Synthesis Board, commented: “The Braglia family is proud to see HAS Healthcare Advanced Synthesis officially launch as a business independent from Helsinn. It is a testament to the team’s sustained commitment to delivering tailored solutions to its clients and its focus on quality, reliability, supply chain management and safety. I would like to personally thank Waldo Mossi for his 27 years of service and am delighted that he has accepted the new role of CEO. Waldo, alongside the HAS Healthcare Advanced Synthesis Board, will form the leadership team to guide the company on its next strategic steps as a leading full-service CDMO delivering high-quality exclusive, personalized solutions to its healthcare clients.”

About HAS Healthcare Advanced Synthesis

HAS Healthcare Advanced Synthesis is a full-service CDMO committed to providing a reliable, first-class and tailor-made offering. The company develops and manufactures Active Pharmaceutical Ingredients (APIs), cGMP Advanced Intermediates, High Potency APIs (HPAPIs) and anticancer compounds for its clients from clinical to commercial supply, on an exclusive basis.

The production plant is located in Biasca, Switzerland and was established in 1984. The site is routinely inspected by the FDA, SwissMedic, and other global regulatory agencies. Production scale ranges from grams to tens of kilograms for HPAPIs and Anticancer compounds from kilograms up to tens of tons (APIs) in plants fully dedicated to cGMP manufacturing.

Please visit our new website: https://www.hashealthcare.com

For more information:
HAS Healthcare Advanced Synthesis Media Contact

Biasca, Switzerland

Giulia Rigonalli

Tel: +41 (0) 91 873 94 00

Email:   mediarelations@hashealthcare.com

For more information, please visit https://www.hashealthcare.com

Latest News

AscendEX Lists the Marvelous NFT Token, MNFT

International, Jan. 13, 2022 (GLOBE NEWSWIRE) — AscendEX is excited to announce the listing of the Marvelous NFT Token (MNFT) under the trading pair MNFT/USDT on AscendEX starting on January 14 at 5:30 p.m. UTC. Marvelous NFTs is a blockchain game development company and the official intellectual property licensee of Bad Days, a decentralized strategy […]

AscendEX Lists Battle of Guardians Token, BGS

International, Jan. 13, 2022 (GLOBE NEWSWIRE) — AscendEX is thrilled to announce the listing of the Battle of Guardians Share Token (BGS) under the trading pair BGS/USDT starting on January 14th at 2 p.m. UTC. Battle of Guardians (BOG) is a real-time, multiplayer NFT fighting game that allows players to utilize their NFT assets as […]

ขยายเวลาในการส่งผลงานเข้าตัดสินรางวัล Stevie® Awards สำหรับการขายและบริการลูกค้าประจำปี 2565

ผู้เข้ารับการคัดเลือกสามารถเสนอชื่อเข้าชิงรางวัลการขายและบริการลูกค้าอันดับหนึ่งได้จนถึงวันที่ 2 กุมภาพันธ์ FAIRFAX, Va., Jan. 14, 2022 (GLOBE NEWSWIRE) — เนื่องจากความต้องการที่ได้รับความนิยมอย่างล้นหลาม ทีมงานรางวัล Stevie® Awards จึงได้ขยายกำหนดเวลาส่งผลงานเข้าตัดสินรางวัล Stevie® Awards สำหรับการขายและบริการลูกค้า ประจำปี ครั้งที่ 16 ไปเป็นวันพุธที่ 2 กุมภาพันธ์ โดยกำหนดเวลาเดิมคือวันที่ 12 มกราคม รางวัลนี้เป็นรางวัลชั้นสูงของโลกสำหรับผู้เชี่ยวชาญ ทีมงาน และองค์กรด้านการขายและบริการลูกค้า ท่านสามารถศึกษาชุดข้อมูลการสมัครและรายละเอียดการแข่งขันแบบสมบูรณ์ได้ที่http://www.StevieAwards.com/Sales ผู้ที่ได้รับการเสนอชื่อประกอบด้วย แผนก ทีมงาน และผู้เชี่ยวชาญจากทั่วโลกที่ทำงานด้านการบริการลูกค้า ศูนย์ติดต่อ การพัฒนาธุรกิจ และการขาย ผู้ให้บริการผลิตภัณฑ์และบริการและโซลูชันใหม่ที่ให้บริการแก่ผู้เชี่ยวชาญดังกล่าวก็มีสิทธิ์เสนอชื่อด้วยเช่นกัน โดยรางวัลประจำปี 2565 จะประมวลจากความสำเร็จตั้งแต่วันที่ 1 กรกฎาคม 2562 และจะประกาศชื่อผู้ชนะในวันที่ 28 กุมภาพันธ์ 2565 ซึ่งจะมีพิธีมอบรางวัลแบบเสมือนจริงแก่ผู้ชนะ Stevie Award ระดับทอง เงิน […]

Amlan International to Present New Research During International Production and Processing Expo (IPPE)

Oral abstract presentations will center on new natural feed additive solutions to support optimal intestinal health and microbial balance in poultry. Two Amlan-sponsored TECHTalks presentations by leading industry researchers will focus on the impact of intestinal microbiota, applications of a Mycotoxin Risk algorithm, and opportunities to improve intestinal health. IPPE attendees will be able to […]